InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,458.87
(
0.40%
)
Post# of 252203
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119844
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 193725

Friday, 07/31/2015 9:17:14 PM

Friday, July 31, 2015 9:17:14 PM

Post# of 252203
Re: AMGN’s threat from FoBs

http://www.wsj.com/articles/amgen-to-undergo-experimental-treatment-1438363128

At about 18 times forward earnings, Amgen stock isn’t especially pricey for a large biotech. But…for Amgen to maintain or grow its valuation, biosimilars need to arrive with a whimper, not a roar.

In 2Q15, 36% of AMGN’s product sales came from Epogen, Neupogen, and Neulasta, which are off-patent in the US and several other major countries.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up